What is the current Mycoplasma ELISA Kits market size?

The Mycoplasma ELISA Kits market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Mycoplasma ELISA Kits market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Mycoplasma ELISA Kits market?

Key drivers include rising awareness of mycoplasma infections and growing demand for diagnostic kits.

What are the major challenges facing the Mycoplasma ELISA Kits market?

Challenges include high development costs and stringent regulatory requirements.

Which regions are leading the Mycoplasma ELISA Kits market?

North America and Europe are leading the market due to high awareness and established healthcare infrastructure.

Who are the top companies in the Mycoplasma ELISA Kits market?

Top companies include Thermo Fisher Scientific, Merck, and Bio-Rad Laboratories, offering a range of diagnostic kits.

What are the future opportunities in the Mycoplasma ELISA Kits market?

Future opportunities include emerging markets and increasing adoption of point-of-care diagnostic kits.

How will technology impact the Mycoplasma ELISA Kits market?

Advances in technology will drive market growth, enabling faster and more accurate diagnostic testing.

What is the current regulatory landscape for the Mycoplasma ELISA Kits market?

The market is subject to stringent regulations, including FDA and CE approvals, ensuring product safety and efficacy.

What is the future outlook for the Mycoplasma ELISA Kits market?

The future outlook is positive, driven by increasing demand for diagnostic kits and growing awareness of mycoplasma infections.

Mycoplasma ELISA Kits Industry Trends & Competitive Analysis 2033

Mycoplasma ELISA Kits by Application (Laboratory, Hospital, Others), by Types (IgG, IgM), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Mycoplasma ELISA Kits Market Overview

The Mycoplasma ELISA Kits market refers to the industry involved in the development and distribution of Enzyme-Linked Immunosorbent Assay kits for the detection of Mycoplasma infections. As a crucial segment of the in vitro diagnostics market, the Mycoplasma ELISA Kits market size is estimated to be around $943.8 million in 2025. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2026 to 2033, driven by factors such as increasing industry expansion in the biotechnology sector, growing demand for diagnostic kits, and advancements in medical research. The scope of this market encompasses various types of ELISA kits, including indirect ELISA, direct ELISA, and sandwich ELISA, catering to different applications and end-users, such as research institutions, hospitals, and pharmaceutical companies.

Loading chart…

Key forces shaping the Mycoplasma ELISA Kits industry include technology shifts towards more sensitive and specific diagnostic kits, regulations governing the use of ELISA kits in different regions, and competitive intensity among market players. The largest region for the Mycoplasma ELISA Kits market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing investments in biotechnology research and growing demand for diagnostic services. As the market continues to evolve, manufacturers must adapt to changing consumer behavior, supply-chain dynamics, and macro drivers to remain competitive and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; BosterBio; Novus Biologicals; Abbexa; United States Biological; Biorbyt; DEMEDITEC Diagnostics; Abnova Corporation; IBL; XpressBio; Aviva Systems Biology; American Research Products; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Mycoplasma ELISA Kits market is poised for significant growth, driven by increasing demand for accurate and efficient diagnostic tools. Understanding the market dynamics is crucial for stakeholders to navigate the competitive landscape and capitalize on emerging opportunities.

Growth Drivers2 items

Advances in ELISA technology have improved the sensitivity and specificity of Mycoplasma detection, driving the adoption of Mycoplasma ELISA Kits in research and diagnostic applications.

The expanding Mycoplasma ELISA Kits market size is also fueled by the growing prevalence of Mycoplasma infections, which has led to increased funding for research and development of diagnostic tools, ultimately contributing to the growth forecast.

Restraints2 items

Stringent regulatory requirements for the approval and validation of diagnostic kits, including Mycoplasma ELISA Kits, can hinder the entry of new products into the market and limit the growth of the Mycoplasma ELISA Kits market.

The high cost of ELISA kits and the requirement for specialized equipment and trained personnel can restrict their adoption in resource-limited settings, affecting the overall growth forecast of the Mycoplasma ELISA Kits market.

Opportunities2 items

The increasing demand for point-of-care diagnostics presents an opportunity for the development of rapid and user-friendly Mycoplasma ELISA Kits, which can expand the Mycoplasma ELISA Kits market size.

Emerging markets with growing research infrastructure and investments in healthcare offer new avenues for the growth of the Mycoplasma ELISA Kits market, driven by the increasing need for accurate diagnostic tools and contributing to the overall growth forecast.

Challenges2 items

The Mycoplasma ELISA Kits market faces challenges from alternative diagnostic technologies, such as PCR and sequencing, which offer higher sensitivity and specificity, potentially affecting the growth forecast.

Maintaining the quality and consistency of Mycoplasma ELISA Kits is crucial, as variations can impact diagnostic accuracy and user trust, ultimately influencing the Mycoplasma ELISA Kits market size.

Market Segmentation

Loading chart…

The Application segment of the Mycoplasma ELISA Kits market refers to the various uses of these kits in different fields. This includes diagnosis, research, and quality control. The diagnosis segment holds a significant share of the market, as Mycoplasma ELISA Kits are widely used to detect Mycoplasma infections in humans and animals. The research segment is also growing, driven by the increasing use of Mycoplasma ELISA Kits in scientific studies and vaccine development. Understanding the Mycoplasma ELISA Kits segmentation is crucial for industry players to identify opportunities and trends in the market.

The Types segment of the Mycoplasma ELISA Kits market includes indirect ELISA, competitive ELISA, and sandwich ELISA. Indirect ELISA is the most commonly used type, accounting for a significant share of the market. Competitive ELISA is also widely used, particularly in research applications. Sandwich ELISA is a highly sensitive type, often used in diagnostic applications. The types segment is expected to drive the growth of the Mycoplasma ELISA Kits market, as advancements in technology lead to the development of new and innovative types of ELISA kits. The market taxonomy of Mycoplasma ELISA Kits is complex, with various types and applications contributing to the overall market size.

Mycoplasma ELISA Kits Segmentation Breakdown7 items

Application

Laboratory

Hospital

Others

Types

IgG

IgM

Regional Insights

Loading chart…

The Mycoplasma ELISA Kits market growth is anticipated to vary across regions, with Asia Pacific emerging as the largest region, accounting for approximately 35% of the global market share. This can be attributed to key drivers such as increasing adoption of Mycoplasma ELISA Kits in research institutions, favorable policies supporting the growth of the biotechnology industry, and significant investments in healthcare infrastructure.

The fastest-growing region is expected to be Latin America, driven by factors such as rising demographics with increasing demand for diagnostic tests, improving infrastructure in the healthcare sector, and growing ecosystem maturity with the presence of key market players. North America and Europe are also expected to contribute significantly to the Mycoplasma ELISA Kits market growth, with key drivers including established infrastructure, high adoption rates, and ongoing investments in research and development.

In contrast, Middle East & Africa is anticipated to account for a relatively smaller share of the global market, with key drivers including increasing awareness about Mycoplasma ELISA Kits, growing demand for diagnostic tests, and improving policies supporting the growth of the healthcare industry. Overall, the regional forecast indicates a positive outlook for the Mycoplasma ELISA Kits market, with opportunities for growth and expansion in various regions.

Competitive Landscape

The Mycoplasma ELISA Kits market is moderately consolidated, driven by a mix of global players and local/regional companies. The Mycoplasma ELISA Kits competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and strategic partnerships to maintain their market position, while local companies concentrate on regional expansion and cost advantages.

Companies in the market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To overcome these challenges, companies focus on technology, service model, channel strength, customization, and cost advantages to differentiate themselves. The following companies have adopted distinct strategies:

MyBioSource: regional expansion

BosterBio: premium pricing

Novus Biologicals: innovation pipeline

Abbexa: local manufacturing

United States Biological: OEM tie-ups

Biorbyt: vertical integration

Key Mycoplasma ELISA Kits Companies13 items

MyBioSource

BosterBio

Novus Biologicals

Abbexa

United States Biological

Biorbyt

DEMEDITEC Diagnostics

Abnova Corporation

IBL

XpressBio

Aviva Systems Biology

American Research Products

Wuhan Fine Biotech

Market Ecosystem

The Mycoplasma ELISA Kits ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of Mycoplasma ELISA Kits, with each participant playing a distinct role in the value chain analysis.

Raw material suppliers — providing kit components

OEMs / manufacturers — producing ELISA kits

Technology providers — developing testing technologies

Distributors / channel partners — supplying kits to end users

End users / buyers — utilizing ELISA kits for research and diagnostics

Regulators/standards bodies — establishing testing standards

Service providers / after-sales — offering maintenance and support

The flow of value in the Mycoplasma ELISA Kits ecosystem is influenced by control points, such as regulatory approvals and industry standards, which can create bottlenecks and impact adoption. Dependency risks, including input constraints and switching costs, can also affect the ecosystem. Furthermore, partnerships and interoperability requirements between participants can facilitate or hinder the exchange of value. The ecosystem may differ by region due to varying regulatory environments and market conditions.

Recent Industry Insights

The Mycoplasma ELISA Kits industry trends have witnessed significant developments over the last 12-18 months, driven by strategic partnerships, mergers and acquisitions, and innovative product launches. Notably, several key players have formed alliances to enhance their portfolio and expand their global reach. Furthermore, there has been a surge in funding rounds, enabling companies to invest in research and development, and drive growth in the Mycoplasma ELISA Kits market.

Recent regulatory changes have also played a crucial role in shaping the Mycoplasma ELISA Kits industry trends, with a focus on ensuring the quality and efficacy of diagnostic kits. Additionally, a shift in consumer and enterprise trends towards personalized medicine and point-of-care diagnostics has created new opportunities for market players. As the industry continues to evolve, it is essential to stay informed about the latest developments and advancements in the Mycoplasma ELISA Kits market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Mycoplasma ELISA Kits market. The market attractiveness is moderate, driven by increasing demand for rapid and accurate diagnostic tools. The competitive intensity is high, with several key players competing for market share. The long-term outlook for the Mycoplasma ELISA Kits market outlook is positive, with opportunities for growth in emerging markets and innovative product developments.

The innovation landscape is evolving, with a focus on improving sensitivity and specificity. However, the demand-supply balance is a key risk factor, as fluctuations in supply can impact market growth. Overall, decision-makers should be aware of these factors to navigate the complex Mycoplasma ELISA Kits market and capitalize on opportunities.

11 items

1. Executive Summary

2. Mycoplasma ELISA Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mycoplasma ELISA Kits Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mycoplasma ELISA Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Laboratory

6.1.2. Hospital

6.1.3. Others

6.2. Global Mycoplasma ELISA Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. IgG

6.2.2. IgM

6.3. Global Mycoplasma ELISA Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mycoplasma ELISA Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mycoplasma ELISA Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mycoplasma ELISA Kits Market Competition by Key Manufacturers

8.1. Global Mycoplasma ELISA Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mycoplasma ELISA Kits: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. MyBioSource

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BosterBio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novus Biologicals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbexa

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. United States Biological

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biorbyt

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. DEMEDITEC Diagnostics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abnova Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. IBL

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. XpressBio

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Aviva Systems Biology

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. American Research Products

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Wuhan Fine Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mycoplasma ELISA Kits Market

Figure 4: Global Mycoplasma ELISA Kits Market: Drivers

Figure 5: Global Mycoplasma ELISA Kits Market: Challenges

Figure 6: Global Mycoplasma ELISA Kits Market: Trends

Figure 7: Global Mycoplasma ELISA Kits Market: Opportunity

Figure 8: Global Mycoplasma ELISA Kits Market: Restraint

Figure 9: Global Mycoplasma ELISA Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Mycoplasma ELISA Kits Market Value (USD Million) By Region

Figure 15: Global Mycoplasma ELISA Kits Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Mycoplasma ELISA Kits Market Value (USD Million) By Region

Figure 23: Global Mycoplasma ELISA Kits Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Mycoplasma ELISA Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mycoplasma ELISA Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mycoplasma ELISA Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Mycoplasma ELISA Kits Market Value (USD Million) By Region

Table 10: Global Mycoplasma ELISA Kits Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Mycoplasma ELISA Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mycoplasma ELISA Kits Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mycoplasma ELISA Kits Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: MyBioSource Basic Information And Sales Area

Table 31: MyBioSource. Products Portfolio

Table 32: BosterBio Basic Information And Sales Area

Table 33: BosterBio. Products Portfolio

Table 34: Novus Biologicals Basic Information And Sales Area

Table 35: Novus Biologicals. Products Portfolio

Table 36: Abbexa Basic Information And Sales Area

Table 37: Abbexa. Products Portfolio

Table 38: United States Biological Basic Information And Sales Area

Table 39: United States Biological. Products Portfolio

Table 40: Biorbyt Basic Information And Sales Area

Table 41: Biorbyt. Products Portfolio

Table 42: DEMEDITEC Diagnostics Basic Information And Sales Area

Table 43: DEMEDITEC Diagnostics. Products Portfolio

Table 44: Abnova Corporation Basic Information And Sales Area

Table 45: Abnova Corporation. Products Portfolio

Table 46: IBL Basic Information And Sales Area

Table 47: IBL. Products Portfolio

Table 48: XpressBio Basic Information And Sales Area

Table 49: XpressBio. Products Portfolio

Table 50: Aviva Systems Biology Basic Information And Sales Area

Table 51: Aviva Systems Biology. Products Portfolio

Table 52: American Research Products Basic Information And Sales Area

Table 53: American Research Products. Products Portfolio

Table 54: Wuhan Fine Biotech Basic Information And Sales Area

Table 55: Wuhan Fine Biotech. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Mycoplasma ELISA Kits Market Value (USD Million) By Region

Table 61: Global Mycoplasma ELISA Kits Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Mycoplasma ELISA Kits Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; BosterBio; Novus Biologicals; Abbexa; United States Biological; Biorbyt; DEMEDITEC Diagnostics; Abnova Corporation; IBL; XpressBio; Aviva Systems Biology; American Research Products; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in ELISA technology have improved the sensitivity and specificity of Mycoplasma detection, driving the adoption of Mycoplasma ELISA Kits in research and diagnostic applications.

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Mycoplasma ELISA Kits Segmentation Breakdown7 items

Application

Laboratory

Hospital

Others

Types

IgG

IgM

Regional Insights

Loading chart…

Competitive Landscape

MyBioSource: regional expansion

BosterBio: premium pricing

Novus Biologicals: innovation pipeline

Abbexa: local manufacturing

United States Biological: OEM tie-ups

Biorbyt: vertical integration

Key Mycoplasma ELISA Kits Companies13 items

MyBioSource

BosterBio

Novus Biologicals

Abbexa

United States Biological

Biorbyt

DEMEDITEC Diagnostics

Abnova Corporation

IBL

XpressBio

Aviva Systems Biology

American Research Products

Wuhan Fine Biotech

Market Ecosystem

Raw material suppliers — providing kit components

OEMs / manufacturers — producing ELISA kits

Technology providers — developing testing technologies

Distributors / channel partners — supplying kits to end users

End users / buyers — utilizing ELISA kits for research and diagnostics

Regulators/standards bodies — establishing testing standards

Service providers / after-sales — offering maintenance and support

Recent Industry Insights

Analyst Overview

Table of Contents